How to manage tumour radiotherapy during COVID-19 pandemic?

摘要

At present, the outbreak of novel coronavirus (COVID-19) infection pneumonia, which was first reported in Wuhan city, Hubei province, China, has evolved from locoregional public health events to pandemic public health emergency involving more than 154 countries and regions (Huang et al., 2020). As of 28 March 2020, cumulative identified infection in the world except China is 489,448 cases and 23,193(4.7%) cases of them have passed away. A study reported that cancer patients have higher risk of infection, severe symptoms, more rapid deterioration and poorer outcome once infected, compared with non-cancer patients, due to older age, smoking history, diverse comorbidities and the immunosuppressive status after chemotherapy, surgery or even immune checkpoint blockade (ICB) regimen(Liang et al., 2020).